A Chlamydia trachomatis CPAF-STING agonist conjugate vaccine administered intramuscularly and intradermally is immunogenic in the pig model

1

Chlamydia trachomatis is the leading cause of sexually transmitted infections, necessitating the development of an effective vaccine due to inadequate current treatments.
2

The study utilized a porcine model to evaluate the immunogenicity of three vaccine candidates targeting Chlamydial Protease-like Activity Factor (CPAF).
3

The CPAF-STG1151 conjugate vaccine candidate elicited the strongest systemic T cell response, characterized by significant IFNγ production.
4

Administration method (intramuscular vs. intradermal) did not significantly affect the immune response or cytokine profile in the tested vaccine candidates.
5

The findings support the potential of CPAF-STG1151 as a highly immunogenic subunit vaccine, warranting further investigation into its efficacy and delivery methods.

Frontiers In Immunology

by Leonie Bettin, Christine Unterweger, Maximiliane Dippel, Tamara Borysova, Maria Stadler, Jonathan Harris, James Rozzelle, Daisy Arroyo, Jeff Fairman, Taylor B. Poston, Eric Perouzel, Thierry Lioux, Juan F. Hernandez-Franco, Harm HogenEsch, Andrea Buzanich-Ladinig, Toni Darville, Tobias Käser
May 1, 2026

1